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ABSTRACT
TYPE H ESTROGEN BINDING SITE AGONIST: THE SYNTHESIS 
AND BIOLOGICAL EVALUATION OF THE ENANTIOMERS 
OF METHYL-PARA-HYDROXYPHENYLLACTATE (MEHPLA)
Lester G. Pretlow 
Old Dominion University, 1997 
Co-Directors: Dr. Roy L. Williams 
Dr. Mark S. Elliott
The function of the type Q estrogen binding site (EBS) has yet to be determined. 
However, a high affinity ligand for the binding site has been identified through HPLC 
and GC-MS. This ligand, MeHPLA, bears a structural relationship to a group of 
compounds called “phytoestrogens” which, along with MeHPLA, have been observed to 
suppress the cellular proliferation of estrogen sensitive MCF-7 breast cancer cells in 
vitro. Additionally, MeHPLA has been observed to suppress the growth of rat uteri in 
vivo. The high affinity of MeHPLA for the type II EBS suggests that this interaction is 
responsible for the observed suppression of cell growth. If  this interaction is the mode of 
cell growth suppression, then the chiral center o f MeHPLA might be expected to change 
the binding affinity of the ligand and the associated cellular activity. In this study, the 
enantiomers of MeHPLA were synthesized and separated by three methods. The 
methods included the use of the enantioselective catalyst, oxazoborolidine, the enzyme, 
lactate dehydrogenase, and the diastereomeric separation using a chiral amine. When the 
methods were compared, it was found that the method using the diastereomeric 
separation gave the superior yield for the two enantiomers. Binding studies for the
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enantiomers to the type II EBS showed that the L-MeHPLA isomer has a higher affinity 
for the binding site. However, binding affinity did not translate into cell growth 
suppression. Both enantiomers had the equivalent ability to suppress cellular growth.
The conclusion is that the interaction of MeHPLA with the type H binding site may not 
be the mode by which cell growth suppression is achieved. This was supported by the 
evaluation of MeHPLA against LnCap prostate cancer cells and HxGC3 colon cancer 
cells in culture. Type H binding sites have been observed in prostate and colon cancer 
cell lines. However, their existance in these particular cell lines have not been confirmed. 
Some cellular growth suppression was observed in these cell lines upon treatment with 
MeHPLA. The possible function of MeHPLA was also compared to other 
phytoestrogens that appear to act independantly of the type II EBS Their activity was 
compared to a group of compounds known as xenoestrogens. MeHPLA, phytoestrogens, 
and xenoestrogens have the ability to stimulate, inhibit, or compromise normal or 
malignant cells with in the reproductive tract
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INTRODUCTION
The differential binding nature o f estrogen receptors have been observed in 
cytosolic and nuclear fractions derived from several cell lines. This binding is 
concentration dependent and is characterized by a biphasic binding curve (1). At 
physiological concentrations, estradiol binds the estrogen receptor. However, in cytosolic 
and nuclear cell-free preparations, if the concentration o f estradiol is increased above 
physiological levels, a second binding site is observed and is eventually saturated (Fig.
1). Since the concentration of estradiol would not reach these levels under physiological 
conditions, it is unlikely that estradiol is the endogenous ligand for this second binding 
site. This differential binding has given rise to the present classification of estrogen 
receptors, designated as the type I estrogen receptor (ER) and the type II estrogen binding 
site (EBS).
The type II EBS has been labeled the “bioflavonoid receptor,” because of its 
ability to bind a group of compounds known as phytoestrogens. Through this 
association, phytoestrogens appear to have a protective value against cancer (48). It is 
possible that phytoestrogens activate the type II EBS to interact with a cell’s 
transcriptional machinery to inhibit the protein production associated with cell 
proliferation (48-49). Recently, unique endogenous flavonoid-like ligands have been 
observed to bind to the type II EBS and modulate the cellular proliferation that is 
associated with estradiol binding to the type I ER Extraction and chromatography of 
these ligands from normal and malignant tissue
My journal model is The Journal o f  Biological Chemistry.
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Fig. 1. Biphasic Binding Curve for Estrogen Receptors with ^-estradiol. Distinct 
binding sites are exemplified at different concentrations of hormone. The first site 
becomes saturated between 1-10 nM and the second site between 10-30 nM (1).
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have revealed two components. One is designated by an alpha binding activity and the 
other designated by beta (2). Even more compelling, the beta component is present in 
normal tissue but absent in malignant tissue and has been observed to inhibit the growth 
of MCF-7 breast cancer cells in vitro (2). This evidence suggests that the beta component 
may bind to the nuclear type II EBS and modulate cellular proliferation associated with 
estradiol binding at the type I ER (2). Using HPLC and GC-MS, the beta component has 
been identified as methyl-p-hydroxyphenyllactate (MeHPLA) (2) The chemical structure 
of MeHPLA is shown in Fig. 2.
An endogenous ligand for the type n  EBS was first suspected when it was 
observed that cytosolic homogenates increased 3H-estradiol binding activity upon dilution 
(3). These homogenates were subsequently chromatographed and the alpha and beta 
components were collected and assessed for binding activity. This assessment confirmed 
that the beta peak, MeHPLA, had significant activity as the ligand for the type II EBS.
MeHPLA has subsequently been identified as a ubiquitous substance of all normal 
tissues. Its presence has been detected in uterine, serum, breast, and liver tissue (3). The 
origin of this endogenous ligand appears to be from the degradation o f certain dietary 
bioflavonoids and/or tyrosine metabolism (4-5). Competitive binding analysis with 
3H-estradiol has revealed that MeHPLA binds to nuclear type II EBS’s with high affinity 
(Kd = 4 nM), and physiological levels blocked estradiol stimulation o f uterine growth in 
vivo and inhibited the growth o f MCF-7 human breast cancer cells in vitro (2).
The alpha component was found to be the corresponding parent acid, para- 
hydroxyphenyllactic acid (HPLA). HPLA is a hydrolysis product of MeHPLA and is 
likely derived from specific esterase(s) activity in cancer cells (2). It is therefore possible
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Fig. 2. D-Methyl-para-hydroxyphenyllactate (MeHPLA). Endogenous ligand 
observed to bind to the type II EBS (2).
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that the absence o f MeHPLA is a marker of malignant tissue. HPLA has a low affinity 
(Kd is 30-40 times larger) for the type II EBS and does not block the uterotropic 
response to estradiol or inhibit MCF-7 cell growth (2). Such evidence seems to confirm 
the regulatory properties of MeHPLA.
One property of MeHPLA that has not been studied is the relative binding of the 
different stereoisomers (L,D) of MeHPLA. To date, binding and growth studies have 
used a racemic mixture of L (S) and D (R) isomers. It is therefore possible that one of the 
enantiomers may have a greater binding affinity for the type II receptor and a greater 
ability to inhibit cellular proliferation. HPLA found in the urine of patients with 
tyrosyluria is the L-isomer, therefore it is likely that the natural isomer o f MeHPLA is 
“L” (2). The objective of this research was to synthesize the L and D isomers of 
MeHPLA, purify them, and test their binding affinity for nuclear type II EBS's and their 
ability to inhibit cellular proliferation in MCF-7 cells in culture. Since MeHPLA is a
ubiquitious endogenous compound, the implications of its regulatory effects may be more 
far reaching than currently believed. Several cells lines were tested with the isomers of 
MeHPLA to ascertain possible regulatory effects beyond that of estrogen sensitive cell 
lines. Additionally, a  correlation will be made between MeHPLA, phytoestrogens and a 
group of compounds known as xenoestrogens, which are synthetic componds that mimic 
the activity of estrogens, such as (DDT) and diethylstilbestrol (DES).
Background and Significance
Breast cancer is one of the most common forms of cancer. The American Cancer 
Society estimates that 183,000 new cases will be reported in 1997 and the number of
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deaths attributed to breast cancer this year is estimated at 46,300 (6). Though it is 
primarily a disease of women, breast cancer can also occur in men. Contributing causes 
have been linked to cigarette smoking, alcohol consumption, diet, oral contraceptives, 
body size, radiation, and psychosocial influences (7). However, the preceding possible 
causes have not addressed specific answers or the etiology o f breast cancer.
For many years, it has been known that estrogen stimulates the growth of some 
breast cancers, and the growth of these cancers is inhibited by antiestrogens (8). 
Classically, hormone action involves the synthesis and secretion of hormone by 
endocrine cells. The hormone then travels via the blood stream to its target tissue and 
enters the cell through simple or facilitated diffusion. Once within the cell, hormones 
activate many cellular processes by interacting with cellular proteins (Fig. 3). The 
hormone indicated as having a possible connection to some hormone-related breast 
cancers is estradiol (and its mimics).
Estradiol induces the synthesis o f a large number of enzymes involved in protein 
and nucleic acid synthesis including DNA polymerase, thymidine and uridine kinases, 
thymidylate synthetase, carbamyl phosphate synthetase, aspartate transcarbamylase, and 
dihydro folate reductase (9-10). Physiological concentrations o f estradiol, stimulate 
nucleotide synthesis by both scavenger and de novo biosynthetic pathways (8). Estradiol 
regulates many of these biosynthetic pathways at the mRNA transcriptional level by 
altering the cellular synthesis and/or secretion o f several proteins (11). Synthesized 
proteins include plasminogen activators and collagenolytic enzymes that contribute to 
breast cancer progression by allowing the tumor to digest and traverse encapsulating




Fig. 3. Classical Steroid Hormone Action. Estradiol (white squares) moves through 
the blood stream to target cells and interacts with the estrogen receptor (black rectangle). 
This causes a conformational change in the receptor represented by the black rectangle 
changing into a black circle. This conformational change is known as activation. The 
activated receptor then enters the nucleus and binds to the hormone response element 
(HRE) located on the DNA to activate transcription. Gene transcription produces a 
messenger RNA with a poly A tail which is then translated by the ribosomes into a new 
protein in the cytoplasm (15).
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basement membrane (12). Additionally, these proteins may serve to release mitogenic 
factors like somatomedin C from carrier proteins, thus causing the processing of 
inactive precursor growth factors to active species (13). This kind o f mitogenic activation 
by estradiol has also been shown to induce surface receptors or binding proteins for 
laminin in MCF-7 breast cancer cells (14). The laminin receptor mediates attachment 
of cells to basement membrane laminin to contribute to invasiveness of tumor cells and 
to promote colonization of new tissue areas. In vitro, estradiol treatment of MCF-7 cells 
increases laminin binding to ardfically laminin-coated membranes and the migration of 
the same cells across an artificial membrane toward a difiusable source of laminin (14). 
Estradiol activates these physiological effects through its interaction with the type I ER.
The type I ER is part o f the largest family of intracellular transcription factors in 
eukaryotes (15). The Steroid Hormone Receptor Superfamily includes receptors for 
estrogen, progesterone, glucocorticoids, mineralocorticoids, and androgens. In addition, 
it includes receptors for vitamin D, thyroid hormone, androgens, retinoic acid, 9-cis- 
retinoic acid, and ecdysone. The type I ER exists as an inactive apoprotein in the 
cytoplasm or nucleus. Known as a latent transcriptional activator, upon binding estradiol, 
the receptor goes through a series of conformational changes knows as transformation. 
This allows the type I ER to bind an enhancer region (estrogen response element or ERE) 
of DNA that regulates transcription.
The structure of the type I ER may be divided into several functional domains 
(Fig. 4) (15). From the N-terminal, the A/B domain is the most highly variable region for 
sequence and length. It contains a transactivation function that interacts with the
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transcriptional machinery to activate transcription. The C domain, is the DNA- binding 
domain (DBD). This domains contains two zinc fingers responsible for DNA 
recognition. It also contains sequences that are important for dimerization of the 
receptor. The D domain is a hinged region that is responsible for the conformational 
changes the receptor must undergo for activation. Within the D domain, there is also a 
nuclear localization region. The E domain is the ligand-binding domain (LBD). It is the 
largest domain, containing approximately 250 amino acid residues. Most of these 
residues are important for ligand binding, as confirmed by mutational analysis in which 
mutation compromises the ability of the altered receptor to bind its ligand. Within the 
LBD, small stretches o f amino acid sequences serve as regions important for heat-shock 
protein association, dimerization, nuclear localization, and transactivation. Located at the 
C-terminal, one finds the F domain, which presently has no discernible function and 
deletion of the F domain has no effect on receptor function is unaffected.
The DBD is a globular structure that can be divided into two zinc fingers folded 
into a structural unit, known as Type II or Class II zinc fingers (16). One arm of the zinc 
finger unit recognizes a palindromic region within the 35 base pair ERE (16). Mutational 
analysis of the ERE has revealed that all 35 base pairs are necessary for the strongest 
hormonal response, however, as few as 18 base pairs will yield some response (17-18). A 
13 base pair palindromic region is essential for receptor-DNA binding (18). The type I 
ER binds its response element as a homodimer with the residues of one arm of the zinc 
finger unit interacting with DNA and the other arm interacting to form the dimeric 
complex (19). The formation of the dimeric complex has been shown to be important for 
the binding of the type I ER to the ERE (15).
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The importance o f type I ER dimerization was recently analyzed. Formerly, it 
was observed that estrogen, progesterone, and glucocorticoid receptors bind to DNA as 
dimers (15). Monomers o f the preceding receptors bind to DNA with only low affinity. 
Therefore, any lack of detectable DNA binding in the absence of ligand may be due to an 
inability of receptor to form a dimer. In an experiment, an antibody was used as the 
dimerization agent (one divalent antibody forces two receptor molecules to bind to DNA 
at adjacent sites) in the absence of ligand (15). The divalent antibody induced receptors 
to bind their response element with high affinity.
Thus the role of estrogen in DNA binding is likely to be the induction o f a 
conformational change in the LBD which exposes a major dimerization function present 
in this region (10). The major dimerization region is also occluded by several heat-shock 
proteins, hsp90, hsp70, and hsp56 (20-21). Heat-shock proteins provide protection 
against elevated body temperatures associated with fever. If  body temperature rises above 
a certain threshold, heat-shock proteins are activated to provide structural protection 
against tertiary damage of physiologically active proteins. In the case of hormone 
receptors, upon ligand binding, heat-shock proteins dissociate from the LBD to reveal the 
dimerization region (20-21) (Fig. 5). Heat-shock protein dissociation is caused by 
conformational changes in the hormone receptor upon ligand binding.
Conformational changes in the type I ER upon ligand binding have been 
confirmed using protease digestion procedures (22). Upon binding of the ligand, the 
receptor transforms to a conformation that is either more sensitive or less sensitive to 
protease digestion. It has been shown that the ligand-bound receptor for steroid
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HRE
Fig. 5. Heat-Shock protein (HSP’s) dissociation and receptor dimerization. Upon binding ligand, receptor conformational 
changes causes HSP’s to dissociate, exposing dimerization domains and DNA binding domains for receptor interaction (IS).
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hormones has a more protease insensitive conformation (15). Therefore, one can deduce 
that binding of the ligand sequesters certain regions of the receptor so that a protease is 
unable to attack those regions. It is this sequestering of certain regions of the receptor 
that leads to another aspect of receptor-ligand interaction.
In vivo, there are ligands that can act as antagonist or partial agonist to hormone 
receptors. It has been shown that these antagonists/partial agonists can induce heat-shock 
protein dissociation and dimerization, but they cannot produce transcriptional activation 
(23). It appears that these ligands are unable to cause the conformational changes that 
folly sequester the appropriate regions of the receptor necessary for complete 
transcriptional activation. Using protease digestion, it has been shown that the 
conformational changes caused by these other ligands, such as the antiestrogen, 
tamoxifen,
are different from those caused by the receptor’s intended hormone (24-26). From these 
results, it was shown that the extreme C-terminus of the LBD acts as an intracellular 
repressor and must be completely sequestered into the receptor or it will block the 
transactivation region of the receptor (27). It is the transactivation region that acts with 
the transcriptional machinery to cause gene activation. Just how the type IE R  interacts 
with the transcriptional machinery to facilitate gene activation and protein production is 
not folly known. It is possible that hormone binding to type I ER enhances or stabilizes 
the formation and activation of the transcriptional machinery (15).
The transcriptional machinery is made up o f at least seven transcription factors 
(TFII A, B, D, J, F, E, and H) that must bind to the DNA-promoter to activate
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transcription (15). These transcription factors bind in a sequential manner and it is 
possible that the type I ER may act anywhere within the sequence. However, it is 
plausible that the type I ER may bind to TFII B and assist it in binding to the preinitiation 
transcriptional machinery, since evidence has shown the TFII B interacts with the 
estrogen receptor, the thyroid receptor and the progesterone receptor (28). The addition 
of TFII B to the transcriptional machinery complex is a rate-limiting step in gene 
activation (15). However, it should be emphasized that the preceding mechanism has not 
been proven and that the type I ER may interact with other components o f the 
transcriptional machinery.
Type I ER's also have other factors that may influence their activation. Many 
receptors are phosphorylated in the ligand unbound state, but become highly 
phosphorylated when bound to ligand (29). Functionally, phosphorylation appears to be 
redundant, and not a switch which turns on the receptor, but appeals to enhance receptor 
activity synergistically. However, phosphorylation has recently been shown to activate 
receptors in the absence o f ligand. In experiments by Denner et al (1990), chicken 
progesterone receptors were activated in the complete absence of progesterone by 
phosphorylation. Ligand-independent activation may also be seen in the presence of 
dopamine, cAMP inducers, and growth factors (30).
Other components in the nuclear millieu may also have an effect on receptor 
activity. Type I ER's are latent transcriptional activators and may be downregulated by 
interaction with certain nuclear components such as Fos and Jun (15). Also, the 
availability of the transcription factors that form the transcriptional machinery complex
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may be regulatory (IS). Lastly, chromatin structure must always be considered as a 
regulatory modulator (15). If chromatin is conformationally unavailable for gene 
transcription, receptors and other transcription factors will be unable to interact with their 
DNA elements.
Conformationally dependent, multi-level regulatory type I ER's may have arisen 
out of a need to control cellular proliferation which supports the idea that increased 
estrogen concentrations have a causal role in some forms of cancer. One function of 
estrogen is to promote cellular proliferation and growth o f sex organ tissues and other 
tissues related to reproduction. If type I ER's were able to dimerize and bind to promoters 
in the absence of ligand, genes could be more easily transactivated and the net result 
might be an increase in cellular proliferation and cancer. Therefore, the various levels of 
conformational activation of type I ER's is another protective feature to prevent unwanted 
gene activation, cellular proliferation, and cancer.
Another protective mechanism o f type I ER's may be related to the heterogeneity 
of estrogen-binding intracellular proteins. Multiple estrogen-binding proteins has been 
discovered in the immature and mature ovariectomized rat uterus (1). Type I ER's 
represent the classical steroid hormone receptor, and binds estradiol with high affinity 
(Kd = I nM) (31). Type II estrogen-binding sites are intracellular nuclear proteins that 
bind estradiol with a lower affinity (KD = 33 nM) (31). Presently, it is not clear whether 
type II EBS's are distinctly different from the steroid hormone receptor family. Type II 
EBS's are stimulated 30-fold by estradiol, while type I ER's remain relatively constant 
(32). This suggests that they are different proteins. Conversely, type II EBS's and type I
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ER's have the same apparent molecular weight, 37K (33). However, nuclear type II 
EBS's are not recognized by rat monoclonal antibodies which readily recognized type I 
ER's (33-34). Though monoclonal antibody studies are not conclusive, it is good 
evidence that the proteins are distinct (32).
Despite decrepancies in the identity o f type II EBS's, one of the most promising 
approaches to an understanding of a more specific mechanism for cellular proliferation in 
breast cancer comes from the recent work o f Markaverich (2) and Scambia (35). Their 
work demonstrates a positive correlation between the incidence of breast cancer and the 
role of type I ER's and nuclear type II EBS's. Both are effected by estrogen, 
phytoestrogens, and flavonoid-like ligands which have been demonstrated to have growth 
inhibitory activity. Urinary excretion o f flavonoid-like ligands is usually high in areas 
with a low risk of breast cancer, and low in areas associated with a high risk of breast 
cancer (36). This strongly suggests that these compounds have cancer protective 
properties.
Specific Aims
The goal of the Enological Research Laboratory at Old Dominion University is to 
study the protective value of natural compounds against various cancer cell lines, such as 
MCF-7, MDA-231, and human fibroblast cells. Natural compounds found in wines are 
polyphenolic, and appear to interact favorably with many cancer cell types to decrease 
their growth. Of particular importance is the effect these phytoestrogens have on breast 
cancer cells which express type I or type II ER’s or both. These polyphenols are
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phytoestrogens because of their ability to bind to ER’s and modulate cellular 
proliferation. MeHPLA is a likely metabolite of phytoestrogen catabolism.
The specific aims o f the research were as follows:
1. Synthesis o f racemic L/D-MeHPLA: A racemic mixture o f HPLA will be methylated 
by diazomethane to yield L/D-MeHPLA.
2. Cytotoxicity o f racemic L/D-MeHPLA on MCF-7 breast cancer cells: A racemic 
mixture of L/D-MeHPLA will be evaluated for toxic levels on MCF-7 breast cancer cells.
The binding affinity of racemic L/D-MeHPLA to type II EBS's will also be evaluated.
3. MethylationofHPPA: Hydroxyphenylpyruvic acid (HPPA) will be methylated by 
diazomethane to yield methyl-p-hydroxyphenylpyruvate (MeHPPA) in preparation for 
enantioselective reduction.
4. Synthesis of the Enantioselective Catalyst: An oxazoborolidine catalyst is 
synthesized following the protocol outlined by E.J. Corey in J. AM. Chem, 1987.
5. Enantioselective Reduction: MeHPPA will be enantioselectively reduced to L and D- 
MeHPLA by the enantioselective catalyst, oxazoborolidine.
6. Synthesis of L-HPLA: HPPA will be enzymatically reduced to L-HPLA by Lactate 
Dehydrogenase. Confirmation of the L-isomer will be accomplished by comparing 
authentic L and D-HPLA with the enzymatically synthesized L-HPLA upon the 
Sumichiral OA 5000 HPLC column which separates the enantiomers of car boxy acids. 
L-HPLA will be purified by HPLC on a semi-prep column. Synthesized L-HPLA will be 
methylated with diazomethane to yield L-MeHPLA.
7. Confirmation o f L and D-isomers: The structure of the produced L and D-MeHPL A
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from the enantioselective reductions will be confirmed by HPLC and GC-MS.
8. Type II EBS Binding Study: L and D-MeHPLA will be evaluated against racemic 
MeHPLA for binding to the type II EBS's.
9. Cell Growth Study: L and D-MeHPLA will be evaluated against a racemic mixture 
for growth effects on MCF-7 and MDA-231 breast cancer cells, HxGC-3 colon cancer 
cells and LNCAP prostate cancer cells.
10. Discuss and correlate the effects MeHPLA, phytoestrogens, and a group of 
compounds known as xenoestrogen and their relationship to malignant diseases. 
Xenoestrogens include a number of insecticides, industrial chemical, and synthetic 
hormone analogs that number in the hundreds and include dichloro-diphenyl- 
trichloroethane (DDT), dioxin, and diethylstilbestrol (DES).
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RESEARCH DESIGN AND METHOD 
Synthesis of racemic L/D-MeHPLA
L/D-HPLA was methylated with diazomethane (Fig. 6). All reagents were 
purchased from the Aldrich Chemical Company. Using a millimole-size N-methyl-N- 
nitro-N-nitrosoguanidine (MNNG) apparatus, 130 mg o f MNNG was added to the inner 
chamber of the generator. To the outer chamber, 2.0 ml of terahydrofuran (THF) was 
added. The two chambers were connected, secured for air tightness, and placed in a zero 
degree ice bath. 600 pi o f 20% NaOH was then added dropwise with an air-tight syringe 
at 5 second intervals to the inner chamber. Diazomethane gas was generated and 
dissolved in the THF giving a yellow color to the solution. The yellow solution was 
pipetted directly onto the L/D-HPLA to yield L/D-MeHPLA. The reaction was complete 
when the reaction solution began to retain the yellow color, indicating an excess of 
diazomethane. The reaction was followed with HPLC by monitoring the disappearance 
of starting material and the appearance of racemic MeHPLA. The Varian HPLC system 
used a C18-AQ analytical column with a 60% water / 40% acetonitrile solution and flow 
rate of 1.0 ml/min. The absorbance of the phenyl ring was detected by an Applied 
Biosystems 7S9A absorbance detector monitoring at 254 nm. Excess diazomethane and 
THF were evaporated under a stream of nitrogen gas to yield the product. L/D-MeHPLA 
was recrystalized in ether to yield the pure product.
Cell growth study of racemic L/D-MeHPLA on MCF-7 breast cancer cells
The MCF-7 breast cancer cell growth study was carried out in the following 
manner. MCF-7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM),
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Fig. 6. Methylation of Racemic HPLA. L/D-HPLA is methylated using a solution of 
diazomethane dissolved in THF.
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containing 10% fetal bovine serum, l|ig/ml ampicilin, and 1 pg/ml insulin. DMEM 
contains no phenol red which is an estrogenic agent and will contribute to the 
proliferation of estrogen receptor positive cells. Cells were subcultured by versene wash 
and trypsinization. Versene scavenges calcium from plated cells so that they can be 
enzymatically cleaved by trypsin from the culture surface. Calcium inhibits trypsin.
Cells were subcultured into eighty-five 33 mm petri dishes and allowed to incubate 24-72 
hours at 37 °C under a 4% C02 atmosphere. After allowing one to three days of growth, 
a control was counted by hemacytometry and was designated as the number of cells on 
Day 0. The growth media was changed on Day 0 and supplemented with L/D-MeHPLA 
in the concentration range of 2 -10 pg/ml.
The cell population density was determined on Days 2,4, and 6. Cell growth 
media was exchanged for fresh media and resupplemented with experimental compounds 
on Days 2 and 4.
Synthesis of MeHPPA
Following the procedure outlined for synthesis of L/D-MeHPLA, HPPA was 
successfully methylated using diazomethane.
Synthesis of the Enantioselective Catalyst
The synthesis o f  the enantioselective catalyst, oxazoborolodine, was carried out in 
the following manner (37) (Fig. 7). In a round bottom flask, one equivalent of 
diphenylhydroxymethyl-pyrrolidine (101 mg) was reacted with 1.1 equivalents of 
methylboronic acid in 5.0 ml THF. The solution was gently stirred and refluxed at 40 °C 
for three hours. The solvent was evaporated under a stream o f nitrogen gas. The solid






c h 3 b h 2
Ph
3 hours Ph
Fig. 7. The Synthesis of the Enantioselective catalyst, Oxazoborolidine.
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was then recrystalized by adding a small amount of ether and allowed to crystalize in the 
freezer over a 48 hour period. The resulting product was confirmed by melting point 
verification (107-124 °C), GC-MS, and reduction of a model compound, acetophenone 
(Fig. 8).
The acetophenone verification of the enantioselective catalyst was done by 
combining 54pl o f acetophenone and 6.95 mg of catalyst in 5 ml o f THF. To this 
solution, 150pl aliquots of 1.0M BH3-THF was added at approximately 15 minute 
intervals. Five minutes after each injection of BH3-THF, a small amount o f the reaction 
solution was taken, mixed with deionized water, and extracted with ethyl acetate. Twenty 
|il of the ethyl acetate extraction was injected on a C18-AQ HPLC column with solvent 
ratio of 40% acetonitrile, 60% water, and a flow of 1 ml/min.
The disappearance of acetophenone was monitored in this manner, along with the 
appearance of phenylethylalcohol.
Enantioselective Redaction of MeHPPA
MeHPPA, was redissolved in THF for enantioselective reduction to MeHPLA. 
Initially, one equivalent of oxaborolidine (6.95 mg) was added to 6 equivalents of BH3- 
THF (150 pi) (37) (Fig. 9). As in the reduction of acetophenone, BH3-THF was added in 
intervals until the starting product disappeared. The enantioselective reduction took place 
in approximately one hour at 25 °C. The catalyst made from the R-pyrolidinemethanol is 
enantioselective for the S-isomer of ketones, while the S-catalyst is selective for the R- 
isomer. Additionally, the same enantioselective reduction was attempted on HPPA. 
However, the acidic proton of HPPA reacted with the catalyst and destroyed it.















Fig. 8. Enantioselective Reduction of Acetophenone. To test the effectiveness of the 
catalyst, the novel compound, acetophenone was reduced. The successful reduction of 
the compound confirmed that the catalyst had been successfully synthesized.

































Fig. 9. Enantioselective Reduction of MeHPPA. Ketones are enantioselectively 
reduced by the oxazoborolidine catalyst. MeHPPA is not a ketone, but contains the 
functional groups of a ketone, thereby making the catalyst was an effective reduction 
agent.
R ep ro d u ced  with p erm issio n  o f  th e  cop yrigh t ow ner. Further reproduction  prohibited w ithout p erm issio n .
26
Confirmation of L and D-MeHPLA synthesized from Enantioselective Reduction
L and D-MeHPLA synthesized from the enantioselective reduction of MeHPPA 
was confirmed by two methods. Reduction products were chromatographed on an 
analytical C18-AQ column in a 60% water / 40% acetonitrile solution with a flow rate of 
1 ml/min. The retention time o f a standard racemic L/D-MeHPLA was compared to the 
retention time of the reduction product Reduction products were purified by HPLC upon 
a semi-prep C18-AQ column with solvent ratio of 40% acetonitrile/60% water and flow 
rate of 2.0 ml/min.
Reduction products were also confirmed by GC-MS. Using a DB-5 capillary 
column and a temperature gradient of 100 to 300 °C, a standard retention time and 
molecular cracking pattern was obtained for a standard of L/D-MeHPLA. This standard 
was compared to the reduction products.
Enzymatic Synthesis of L-HPLA
The enzymatic reduction of HPPA was accomplished using the procedure outlined 
in the Worthington Manual for the enzymatic reduction of pyruvic acid to yield L-lactic 
acid by the enzyme lactate dehydrogenase. Previously, it had been noted that HPPA 
differs from pyruvic acid by the presence of a phenyl group on carbon number 3. This 
similarity allowed for the possibility of enzymatic reduction of HPPA to L-HPLA. 
Subsequently, a reference was found for the endogenous conversion o f L-tyrosine to 
HPPA and finally to L-HPLA, by an enzyme that was later identified as malate 
dehydrogenase (38) (Fig. 10). Such enzymatic reactions are stereospecific.
Reagents
0.2 MTris-HCL, pH 7.3
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6.6 mM NADH in above 0.2 M Tris buffer, pH 7.3 
30 mM HPPA in above 0.2 M Tris buffer, pH 7.3 
Enzyme
Dissolve 1 mg of bovine heart LDH in I ml o f 0.2 Tris buffer, pH 7.3 
Procedure
Pipette into 25 ml round-bottom at room temperature as follows:
Tris-HCl, 0.2 M pH 7.3 11.2 ml
6.6 mM NADH 0.4 ml
30 mM HPPA 1.8 ml
Reactants were allowed to incubate at room temperature for 4-5 minutes to 
equilibrate.
50 pi of I mg/ml LDH in 0.2 M Tris buffer was added and the reaction was allowed to 
proceed for 30 minutes. The reaction was followed by monitoring the disappearance of 
NADH which absorbs at 340 nm. L-HPLA was detected pipetting off approximately 0.5 
ml of reaction solution and filtering off the protein using centricon 3 centrifuge tubes. 20 
pi of filtrate was injected onto Sumichiral 5000 column (2 mM CuS04 in 95% water /  5% 
acetonitrile (ACN) at 1 ml/min, 254 nm) to detect the presence of L-HPLA and residual 
HPPA.
Confirmation of L and D isomers of MeHPLA by Hydrolysis and HPLC
Confirmation of the L and D isomers o f MeHPLA was attempted by converting 
enantioselectively synthesized MeHPLA into L or D HPLA by hydrolysis o f the methyl 
group with a strong base (1M NaOH). Once the hydrolysis was accomplished, L and D- 
HPLA were injected on the Sumichiral OA 5000 column for enantiomeric quantification.
R ep ro d u ced  with p erm issio n  o f  th e  cop yrigh t ow ner. Further reproduction  prohibited w ithout p erm issio n .
glutarate NA D H NAD
CH,
Am inotransferase LD












Fig. 10. Endogenous Pathway for the enzymatic reduction of HPPA to L-HPLA
(39). MeHPLA could be a derived from this endogenous pathway for tyrosine.
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Diastereomeric separation of L/D-HPLA
Racemic solutions o f chiral carboxylic acids can be resolved into 
enantiomerically pure components by reacting the acid with an enantiomerically pure 
chiral amine (40) (Fig. 11). The reaction forms the diastereomeric salt o f the two chiral 
components. Diastereomers are different compounds with different properties and can be 
separated by several different methods. Once the racemates have be separated, they can 
be retrieved by acidification of the solution and extraction of the chiral carboxylic acid. 
Upon heating, 72 mg of R/S-HPLA was reacted with 101 mg of S- 
diphenylpyrolidinemethanol in 10 ml o f THF. After allowing the reaction solution to 
cool, the S-S diastereomer recrystalized from the solution and was subsequently filtered 
off by vacuum filtration. The R-S diastereomer, which remained in the THF, was 
retrieved by evaporating the THF under a stream of nitrogen. The purity of the R-S 
distereomer was further enriched by rinsing the crystals with ether and subsequent 
filtering.
The diastereomeric salts were then dissolved in water and acidified with 5% 
Hydrochloric acid (HC1). The solution was then extracted with ethylacetate to finally 
yield the R-HPLA and the S-HPLA. R and S-HPLA were chromatographed upon the 
Sumi Chiral OA-5000 Column to obtain their enantiomeric purity and confirm that the 
retention times corresponded to the enantiomers. Additionally, the Infra-Red spectra o f a 
standard R/S-HPLA solution was compared to the products from the diastereomeric 
separation. Products were subsequently methylated with diazomethane.
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Fig. 11. Flow Chart of Diastereomeric Separation of L/D-HPLA. The diastereomers 
of racemic HPLA and a chiral amine were synthesized and then separated using 
recrystalization.
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Type IIEBS Binding Study for Experimental Compounds
3H-estradiol binding studies were earned out on cytosolic preparations o f MCF-7 
and MDA-231 breast cancer cells. MCF-7 cells contain type I ER’s and type II EBS’s, 
while MDA-231 contain only the type II EBS. Cells were again cultured in 25 cm2 flasks 
containing 5 ml of DMEM with 10% fetal bovine serum (FBS), and 1 pl/ml insulin.
Cells
were allowed to grow for 48-72 hours at 37 °C. Cells were harvested by removing the 
media, washing in versene, and then trypsinization. Five ml of versene was added to the 
cells to resuspend them and the cells were centrifuged pouring off the versene layer after 
each spin. Approximately, 10 ml of versene was then added to the cells and they were 
homogenized using a dounce-homogenizer. After homogenization, the insoluble cellular 
components were removed by ultra-centrifugation (30,000 x g) and the cytosolic 
preparation was divided among 42 test tubes in 200 pi aliquots. Diethylstilbestrol (DES) 
(1 nM) was added to block all binding to type I ER’s, so that the binding observed was 
only to type II EBS’s. Binding agents (L-MeHPLA, D-MeHPLA, and L/D-MeHPLA) 
were added and allowed to react for 30 minutes at room temperature. Concentrations of 
binding agents were in the range of 100 pM to 1 nM.
3H-estradiol was then added and allowed to incubate for 30 minutes at room 
temperature. Since saturation of type II EBS’s is reported at 30 nM, a 30 nM solution of 
3H-estradiol was used.
After incubation with experimental compounds, bound proteins were precipitated 
with 5% trichloroacetic acid (TCA) on ice and filtered on to glass fiber filter paper by
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vacuum filtration and rinsed with 30 ml of 5% TCA. The glass filters were then placed in 
scintillation vials and 20 ml of scintillation cocktail was add to each vial for 
quantification of bound tritiated estradiol.
Cell Growth Studies with the Enantiomers of MeHPLA
MCF-7 and MDA-231 breast cancer cells, HxGC3 coion cancer cells, and LnCap 
prostate cancer cells were all tested for growth response to the enantiomers o f MeHPLA. 
HxGC3 cells were cultured in modified eagle media (MEM) containing phenol red, 10% 
bovine serum and antibiotics. LNCap cells were cultured in RPM I1640. Each cell line 
was subjected to a 7-10 day growth study depending on how rapidly cells proliferated. 
MDA-231 cells were strikingly more vigorous in their growth rate than the other cell 
lines. The cell study was carried out in 5 days, counting the cells on days 1, 2, and 5.
The concentration range for experimental compounds was 10 pg/ml - 2 pg/ml and all 
cells were counted by hemacytometry.
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EXPERIMENTAL RESULTS
The Chromatographic Separation of L/D-HPLA
Racemic HPLA was separated using the Sumichiral OA 5000 column (Fig. 12). 
The column separates enantiomers of car boxy acids by complexing analytes with Cu 
that is chelated to penicillamine bound to a stationary phase. Analytes react with the 
Cu2+-penicillamine chealate in a manner which allows the enantiomers specific points of 
interaction with the stationary phase. D-enantiomers have three points of interaction and 
are therefore retained on the column longer (41-42). The L-enantiomers have only two 
points of interaction (41-42). By ligand-exchange with Cu2+ and S 042'  in the mobile 
phase, enantiomers are moved down the column to effect separation. Enantiomers elute 
as homodimers held together by ionic copper complexed between them (Fig. 13).
The original experimental strategy was to resolve the enantiomers 
chromatographically and then methylate them in an acidic methanolic solution.
However, the Cu-HPLA complex could not be separated due to the strength of the 
coordinate covalent bounds holding it together. Three approaches were attempted to 
break the bonds. The first involved stirring the complex with a polystyrene resin to 
chelate the copper away from HPLA. The second approach involved acidifying the 
complex with concentrated HCI. The third approach involved the acid catalyzed 
methylation of HPLA. HPLA can be esterified in an acidic methanolic solution. It was 
thought that copper could be removed from the complex by direct esterification. All of 
these methods were unsuccessful. Additionally, it was observed the acid-catalyzed 
methanolic approach to methylation was not the most efficient way to methylate HPLA.
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Fig. 12. Separation of L/D-HPLA on the OA 5000 Column. The first successful 
chromatographic separation of racemic HPLA.
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Synthesis of racemic L/D-MeHPLA
The synthesis of racemic MeHPLA was followed by HPLC. Using an ODS-AQ 
C18 column (4.6 x 250 mm) with previously described solvent ratio and flow rate, L/D- 
HPLA, purchased from the Aldrich Chemical Company, had a retention time of 2.16 - 
2.21 minutes. Upon reaction with diazomethane, synthesized L/D-MeHPLA had a 
retention time o f4.43 - 4.44 minutes (Fig 14). The yield of MeHPLA was approximately 
95.6%.
Methylation of HPPA
Following the same procedure outlined for the methylation of L/D-HPLA, HPPA 
was methylated using diazomethane. The reaction was followed with HPLC and the 
starting material had a retention time of 2.17 - 2.18 minutes. The product, Methyl-p- 
hydroxyphenylpyruvate (MeHPPA), proved to be unstable in the solid state. White 
crystals of MeHPPA rapidly discolored to a yellow oil within 24 hours. The methylation 
of HPPA had a yield of approximately 98%.
A unique property of MeHPPA was revealed from its chromatogram where two 
distinctive peaks suggested the presence of a second product from the methylation 
reaction (Fig. 15-16). Upon further investigation, it was discovered that HPPA exists in a 
ketonic and an enolic form (43). Keto-enol tautomerization is driven by resonance 
stabilization of the enolic form when compared to the ketonic form. The enolic form is 
resonance stabilized by a conjugated system of double bonds.
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Fig. 14. Methylation o f HPLA. ThemethylationofHPLA was followed by HPLC. 
HPLA elutes at 2.16 minutes followed by MeHPLA at 4.4 minutes. The chromatogram 
shows the disappearance of HPLA and the appearance of MeHPLA.
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Fig. 15. Chromatogram of methylated-HPPA. Distinctive peaks of the ketonic and 
enolic form were separated on the ODS-AQ C18 HPLC column.
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Fig. 16 Keto and Enolic form of methylated HPPA. MeHPPA and HPPA exists in an 
equilibrium with the enolic form predominating.
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow ner. Further reproduction  prohibited w ithout p erm issio n .
40
Additionally, the influence of an intramolecular hydrogen bond contributes to the 
stability of the enolic system. The methylated ketonic form had a retention time of 
approximately 5.35 minutes and the enolic form had a retention time of 7.47 minutes.
The chemistry o f HPPA and MeHPPA is such that it exists predominately in the enolic 
form regardless o f the solvent and HPPA exists in the enolic form even in the solid state 
(43). The equilibrium can be enhanced toward the ketonic form by increasing the 
polarity of the solvent, however, it was observed that the enolic form predominated even 
when the solvent system was mostly water.
The NMR o f  HPPA and MeHPPA confirmed the presence of the enolic 
structures. For HPPA a single peak at 6.5 ppm corresponds to a single proton on the C-3 
carbon of the enol form (Fig. 17). There is no peak that corresponds to the two protons 
on the C-3 carbon when it is in the ketonic form.
After methylation of HPPA the NMR of MeHPPA (Fig. 18) shows only the 
presence of the enolic form in a solution of deuterated acetonitrile and D20 . The enolic 
proton on the C-3 carbon absorbs at 7 ppm. The methyl peak is at 4.4 ppm. The peak at 
4.8 ppm corresponds to the presence o f HOD.
Synthesis of the Enantioselectfve Catalyst
The enantioselective catalyst, oxazoborolidine, was synthesized and 
confirmed by its melting point, GC-MS, and the reduction of a model compound, 
acetophenone. The melting point of the oxazoborolidine catalyst was reported in the 
range of 107 - 124 °C (37). Such a large melting point range is due to the ability of the
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Fig. 17. NMR of HPPA. The NMR of HPPA shows the presence of the enolic proton on carbon 3. A peak at 6.5 ppm integrates to 
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Fig. 18. NMR of MeHPPA. The MeNMR of HPPA shows the presence of the enolic proton on carbon 3. A peak at 7.0 ppm 
integrates to one proton and not two protons, as would be expected if the ketone were present.
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catalyst to dimerize, and even trimerize. The more dimerization or trimerizadon present 
in the product the higher the melting point of the catalyst. The crystals of the R-catalyst 
melted at 110 - 115 °C, while crystals of the S-catalyst melted a t 115 - 117 °C. Both 
melting points were in the appropriate range to conclude that the catalyst had been 
successfully synthesized.
Further confirmation of the enantioseiecdve catalyst was accomplished using GC- 
MS. The calculated molecular weight of the oxazoborolidine catalyst is 277 grams/mole.
The mass spect-a of the synthesized catalyst (Fig. 19) shows that the molecular ion 
peak has a molecular weight corresponding to 277 grams/mole.
The synthesized catalyst was then used to reduce a model compound. 
Acetophenone was chosen from the literature (37) and the reduction was carried out as 
described previously. Using HPLC with previously described solvent ratio and flow rate, 
the reaction was followed and the ketone was detected by a peak at 8.10 minutes. As the 
reduction proceeded, this peak at 8.10 minutes disappeared and a peak began to appear at 
6.05 minutes (Fig. 20a). After several minutes, the peak at 8.10 minutes had almost 
completely disappeared to be replaced by the peak at 6.0 minutes (Fig. 20b).
Additionally, a known reductant, sodium borohydride (NaBH4), was used to reduce 
acetophenone for chromatographic comparison against the product made by the 
enantioselective catalyst. NaBH4 reduces ketones to their corresponding alcohols, 
however not enantioselectively. Again, the HPLC chromatogram began with a peak at 
approximately 8.10 minutes which was replaced by a peak at 6.0 minutes as the reduction
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Fig 19. Mass Spectra of Synthesized Oxazoborolidine Catalyst Mass Spectra 
showing the molecular ion peak o f277 g/mole.









Fig. 20. Reduction of acetophenone by enantioselective catalyst, (a) Initial reaction 
mixture shows the presence of acetophenone (8.1 min) and beginning appearance of 
phenylethylaicohoi (6.0 min). (b) As the reaction proceeds to completion, the alcohol 
replaces the ketone.
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of the ketone proceeded. The 6.0 minute peak was analyzed by infrared and found to be 
identical to phenylethylaicohol.
Enantioselective Reduction o f MeHPPA
Even though the enantioselective catalyst effectivity reduced MeHPPA to 
MeHPLA, the major product o f this reduction was not MeHPLA. The chromatogram of 
the reaction mixture (Fig. 21b) using the ODS-AQ C18 column contained two major 
products. The peak at time 4.44 minutes corresponded to MeHPLA and constituted 20% 
of the reaction mixture. Residual enol o f MeHPPA corresponding to 5% o f the reaction 
mixture and had a retention time of 7.26 minutes. Unreacted ketone was present in about 
3% and had a retention time o f 5.33 minutes. The predominant peak o f the reaction 
mixture (72%) o f had a retention time of approximately 3.46 minutes.
The origin of this product was traced back to the starting material and the 
presence of keto-enol tautomerization (21a). The chromatogram o f the starting material 
reveals that approximately 20% percent of MeHPPA is in the ketonic state at the 
beginning of the reaction and 80% is in the enolic state. Since the oxazoborolidine 
catalyst reacts effectively with the carbonyl group of ketones to reduce them to alcohols, 
it was assumed that the catalyst would not react with the enolic form MeHPPA. The 
expectation was that the catalyst would react with the ketone carbonyl exclusively, and as 
the ketone was consumed, the equilibrium would shift more of the enol to the ketone. In 
this manner, the equilibrium would continuously shift from the enol to the ketone o f a 
MeHPPA. This appears not to happen. Since most of the starting material was in the 
enolic form, it appears that the catalyst reacted with the carbonyl of the ester.
R ep ro d u ced  with p erm issio n  o f  th e  cop yrigh t ow ner. Further reproduction  prohibited w ithout p erm issio n .
47
Fig 21. Starting and Final Reduction Product (a) The starting product (MeHPPA) 
shows the presence of the ketonic form and the enolic form of MeHPPA. (b) The final 
reaction mixture shows the presence of residual starting material, MeHPLA, and a major 
product at 3.46 minutes.
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Therefore, the predominant peak at 3.46 minutes corresponds to the product of the 
reduction of the enolic form of MeHPPA. MeHPLA would be formed from the reduction 
of the ketonic form o f MeHPPA. Since only 20% of the starting material was in the 
ketonic form, only a fraction of the starting material is actually in the appropriate state to 
be reduced to MeHPLA. The majority of the starting material was reduced to the major 
product peak at 3.46 minutes. When the reduction reaction was allowed to continue 
without quenching, the MeHPLA peak at 4.44 minutes eventually disappeared and only 
the peak at 3.46 minutes remained. Therefore, the peak at 3.46 minutes is likely the 
double reduction product o f  both carbonyls in MeHPPA. This means that the peak at 
7.26 minutes is most likely the enolic form of MeHPPA while the peak at 5.2 minutes is 
the ketonic form.
Enzymatic Synthesis of L-HPLA
The similarity between the structure of pyruvic acid and HPPA indicated that 
HPPA might undergo enzymatic reduction to L-HPLA using the enzyme Lactate 
Dehydrogenase (LDH). The major structural difference was the addition of a phenol 
group on carbon 3 of pyruvate acid. The question was whether HPPA, with its phenyl 
group on C-3, would fit into the enzyme active site of LDH. Molecular modeling on a 
UNIX SGI was used to obtain preliminary results on the feasibility o f the LDH reduction. 
Molecular modeling showed that the phenol group could fit into 'he active sight of the 
enzyme. A reference was subsequently discovered for the enzymatic reduction of HPPA 
by an enzyme originally called a-Keto-Acid Reductace, later identified as Malate
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Dehydrogenase (38). However, since LDH had already been purchased, it was 
appropriate to attempt the reduction using LDH.
The integrity o f LDH was tested by subjecting the enzyme to a model reduction. 
Pyruvic acid was combined with NADH to see if  reduction occurred in the absence o f 
LDH. The enzymatic reduction o f pyruvic acid to L-lactic acid requires NADH as the 
proton donator. The reaction was followed by a  decrease in absorbance at 340 nm 
corresponding to the consumption o f NADH to NAD. Figure 22a shows that when 
pyruvic acid and NADH were combined in the absence of LDH, no oxidation of NADH 
occurred. However, when LDH was added, there was an immediate decrease in the 
absorbance at 340 nm (Fig. 22b). This indicated that the enzyme was functioning 
properly.
Next, pyruvic was replaced with HPPA. Figure 23 shows the linear decrease in 
the absorbance for NADH. This indicated that the enzyme was oxidizing NADH to NAD 
and possible conversion of HPPA to L-HPLA. However, this was not conclusive for the 
synthesis of L-HPLA.
To further confirm that L-HPLA was the product of the enzymatic reduction of 
HPPA the reaction mixture was analyzed on the Sumi Chiral OA-5000 column was used 
. The reaction mixture was filtered and the filtrate was injected on the chiral column to 
look for the presence o f L-HPLA. Previously, it had been confirmed that no L-HPLA 
was detected in the reaction mixture prior to the LDH reduction. Analysis of the LDH 
reduction mixture produced a peak that corresponded to L-HPLA (Fig. 24a). When the 
filtrate was supplemented with authentic racemic HPLA, there was a corresponding
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Fig. 22. LDH Redaction o f Pyruvic Acid, (a) NADH combined with pyruvic acid is 
not oxidized in the absence o f LDH. NADH maintains its absorbance at 340 nm. (b) 
NADH combined with pyruvic acid and LDH is oxidized as accompanied by a decrease 
in absorbance.
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Fig. 23. The Reduction of HPPA by LDH. HPPA is enzymatically reduced to L- 
HPPA. The reaction is followed by monitoring the decrease in absorbance as NADH is 
oxidized to NAD.
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increase in the size of the L-HPLA peak (Fig. 24b). This was proof that the reduction had 
produced L-HPLA.
LDH was more effective at reducing pyruvate acid than HPPA. The addition of 
the hydroxyphenyl group on carbon-3 o f  HPPA caused a structural hinderance at the 
active site of the enzyme. Therefore, the reduction o f HPPA proceeded slowler than the 
reduction of pyruvate acid. The slowness o f the enzymatic reduction of HPPA was not a 
problem to the further use of the LDH method as the choosen method to produce the 
enantiomers of MeHPLA. However, there were two objections to the further pursuit of 
this procedure.
First, milligram quantities of L-HPLA were needed for the biological study. The 
feasibility of scaling-up an enzymatic reaction to obtain milligram quantities o f product 
seemed unfavorable. Enzymes are designed to react with nanogram quantities of 
substrates, therefore the amount of enzyme needed to synthesize milligram quantities of 
L-HPLA was considered to be prohibitive. Second, the procedure only produces the L- 
enantiomer of HPLA. For the biological study to be comprehensive, both the L and D- 
enantiomer were needed. Because of these limitations, it was decided that the enzymatic 
procedure would no longer be pursued as a viable method for the synthesis of the 
enantiomers.
Confirmation of MeHPLA from Enantioselective Reduction
MeHPLA synthesized from the enantioselective reduction was confirmed by GC- 
MS. Authentic MeHPLA, synthesized from racemic HPLA with diazomethane, was 
analyzed and compared to enantioselectively produced MeHPLA. Figure 25 shows the 
mass spectra for authentic and enantioselectively produced MeHPLA. The mass spectra
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Fig. 24. The Detection of L-HPLA in the Enzymatic Reduction Mixture, (a)
Enzymatically synthesized L-HPLA is detected on the Sumichiral OA 5000 column. A 
peak at 13.69 minutes is indicative L-HPLA. (b) When authentic crystals of L/D-HPLA 
is added to the reaction mixture the peak at 13.85 minutes is proportionally increased.
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Fig. 25. Mass Spectral of Authentic and Enantioselectively Produced MeHPLA.
The mass spectras of authentic (a) and enantioslectively synthesized (b) MeHPLA are 
identical.
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were identical. Mass spectral data, along with HPLC data, confirmed that the 
enantioselective reduction had successfully produced MeHPLA.
Diastereomeric Separation of L/D-HPLA
The diastereomers of L/D-HPLA and the secondary amine, R-diphenylprolinol, 
had distinctive different solubilities in THF. Within minutes after L/D-HPLA and the 
amine had dissolved, crystals began to appear in the solution. These crystals were filtered 
and then chromatographed on the OA 5000 column and were found to be 95% of the 
L-enantiomer of HPLA. These crystals corresponded to the L-R acid-amine 
diastereomer. After work up of the diastereomer with HC1 and extraction of the L-HPLA 
with ethylacetate, the yield of the L-isomer remained 95%.
Having now isolated the L-isomer, it was assumed that the D-R diastereomer was 
the predominant compound left in solution. The THF was evaporated and the residual 
crystals were chromatographed on the OA 5000 column to and found to be the crystals 
were 76% of the D-R diastereomer. The D-R diastereomer was then stirred with ether 
and filtered three times in an effort to increase the percentage of the D-enantiomer. The 
final yield of D-enantiomer, after work up with HC1 and ethylacetate extraction was 85%. 
Figure 26 shows the chromatographic results of the separated L and D-HPLA from the 
diastereomic resolution.
The retention times of separated L and D-HPLA qualitatively demonstrated that 
the diastereomeric resolution had yielded HPLA. However, to insure that the separated 
HPLA was indeed authentic, the IR of L/D-HPLA was compared to the IR o f the 
separated products. Figure 27 shows that the IR’s were identical. Therefore, the products 
from the diastereomeric resolution were the separated enantiomers of HPLA.

















Fig. 26. Diastereomeric Separation of L/D-HPLA. (a) The final results of 
diastereomeric separation of L-HPLA. Chiral HPLC shows that the product is 95% L- 
enantiomer. (b) The final results of diastereomeric separation of D-HPLA. Chiral HPLC 
shows that the product is 85% D-enantiomer.




Fig. 27. IR’s of authentic L/D-HPLA and Diastereomeric Separation Product, (a)
The IR of authentic HPLA with unsubstracted background, (b) The IR o f the product 
(HPLA) from the diastereomeric separation.
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Type IIEBS Binding Study
Figure 28 shows the results o f  the competitive binding 3H-estradiol binding study 
performed on MDA-231 breast cancer cells. MDA-231 are positive for type n  EBS’s, 
but negative for type I ER’s. Therefore, all observed ̂ -estradiol binding was due to 
interaction of analytes with the type II EBS. L-MeHPLA, D-MeHPLA, and racemic 
MeHPLA were observed to effectively compete with 3H-estradiol for type II EBS’s. 
However, L-MeHPLA had approximately 30% greater binding affinity than D-MeHPLA. 
As might be expected, racemic MeHPLA had a binding activity that was between the 
activity of the two enantiomers.
Cell Growth Study of MCF-7 and MDA-231 Breast Cancer Cells
There was no observable difference in the growth effects of the enantiomers of 
MeHPLA on MCF-7 breast cancer cells. L-MeHPLA, D-MeHPLA, and racemic 
MeHPLA, all inhibited cell growth at concentrations between 6-10 pg/ml. However, 
statistically, there was not a significant difference in the suppression of cell growth 
between the two enantiomers. Figure 29 shows the growth inhibition on day 10 for 
MCF-7 breast cancer cells. All data points for the enantiomers have significant overlap.
In comparison to MCF-7 cells, MDA-231 cells were a more vigorous cell-line.
The ten day cell study performed on MCF-7 cells was modified to six days for MDA-231 
cells because of their rapid growth. Control cell numbers for MDA-231 cells reached 1.7 
million per cm2 as compared to only 300,000 per cm2 for MCF-7 cells. Nevertheless, 
significant suppression of cell growth was still observed for higher concentrations of the 
enantiomers between 6-10 pg/ml. Figure 30 shows MDA-231 suppression of cell growth
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Fig. 28. Competitive Binding Assay: MeHPLA versus Tritiated-Estradiol. A
concentration dependent decrease in the binding of tritiated-estradiol is observed as the 
concentration of L or D-MeHPLA is increased. L-MeHPLA appears to have a much 
better ability to bind the type II EBS.
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Fig. 29 Effects of L and D-MeHPLA on MCF-7 human breast cancer cell growth in 
vitro. Cell growth was evaluated by counting the number of cells per dish after 10 days.
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Fig. 30. Effects of L and D-MeHPLA on MDA-231 human breast cancer cell growth 
in vitro. Cell growth is evaluated by counting the number of cells per dish after 6 days.
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after six days of treatment with the enantiomers o f MeHPLA. Again, no significant 
difference is observed in the inhibitory activity for the enantiomers of MeHPLA.
To insure that cells did not die during the middle of the study, cells were counted 
every other day. The results of these counts were plotted to show the daily growth of the 
cells (Fig. 31-3 6) (appendix) versus the concentration o f enantiomeric MeHPLA. Again, 
the most significant growth suppression was seen at high
concentrations of MeHPLA (6-10 pg/ml), with both enantiomers showing equivalent 
activity.
Cell Growth Study of HxGC3 human colon cancer cells and LNCap human prostate 
cancer cells.
Because of the ubiquitous nature of MeHPLA, it was important to obtain data on 
the possible involvement of MeHPLA in the suppression of other cancer cell lines. The 
prevalence of the endogenous receptor for MeHPLA, the type IIEBS, has not been 
determined. However, if  the receptor exists in several other cell line, as it does in MD A- 
231 cells, it is possible that the function of MeHPLA may be broader than currently 
thought. The cell growth studies on HxGC3 colon cells and LNCap prostate cells were 
the first attempt at testing the validity of this hypothesis. Both cell groups were subjected 
to growth conditions that were identical to the study for MCF-7 breast cancer cells.
Figure 37 shows the growth suppression o f HxGC3 colon cancer cells by the 
enantiomers of MeHPLA. Although the rate of cellular proliferation was approximately 
equivalent to MCF-7 cells, the suppression of cell growth was a third less. As was 
observed in both MCF-7 and MDA-231 cells, suppression of cell growth was seen at high








— ■ — D-MatPLA 
- - - - - - - L-MatPLA
— • — DayO
8 1020 4 6
Concentration (^g/ml)
Fig. 37. The Comparison of the effects of L and D-MeHPLA on HxGC3 colon 
cancer cell growth in vitro. Cell growth was evaluated by determining the number of 
cells per dish after 10 days. No significant difference was observed in the effects of L 
and D-MeHPLA.
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concentrations of MeHPLA for both enantiomers. However the suppression of cell 
growth was proportionally less than that o f the MDA or MCF-7 cells.
LNCap prostate cancer cells were thought to be a likely target for cell growth 
suppression by MeHPLA. LNCap cells contain receptors for androgens, which are 
members o f the steroid hormone receptor super family (IS). As previously mentioned, 
this family of receptors includes the estrogen receptor and other receptors that have 
structural and functional similarities. Though the type IIEBS cannot yet be classified as 
a member of the steroid hormone receptor super family, its association with the type IER 
and its interaction with estradiol makes a  plausible link to the receptor super family.
Figure 38 shows the effects of the enantiomers of MeHPLA on LnCap prostate 
cells in vitro. For both enantiomers, no significant suppression of cell growth was 
observed. The number of cells in the control sample was approximately equivalent to the 
number of cells per sample for the highest concentration of analyte. Also, there was no 
difference in suppression seen between the L and D enantiomer.
Figures 39-44 (appendix) shows the ten day growth of HxGC3 and LnCap cells 
treated with the enantiomers of MeHPLA. Suppression of cell growth was seen at higher 
concentrations of MeHPLA for both enantiomers, however, the amount of suppression 
was not significant when compared to the control.












Fig. 38. The Comparison of the effects of L and D MeHPLA on LNCap prostate 
cancer cell growth in vitro. No significant suppression o f growth was observed on day 
10 when compared to the day 10 control.
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DISCUSSION
Comparison of Synthetic Methods
The enantioselective reduction o f MeHPPA required a large quantity of starting 
material (150-200 mg) to yield two to three milligrams of MeHPLA. Seventy percent of 
the starting product, ended up as a product other than MeHPLA due to keto-enol 
tautomerization. Keto-enol tautomerization caused low catalytic yield because most of 
the available starting product was in the wrong conformation to be reduced to L or D- 
MeHPLA. Additionally, both the catalytic and purification procedures for the 
enantioselective reduction were labor intensive. The reduction had to be carefully 
monitored because the catalyst would reduce any available carbonyl group. Once 
MeHPLA was made, it was not protected from further attack by the catalyst HPLC 
injections were made at 15 minute intervals over 90 minutes to insure that the reaction 
was quenched at the peak of MeHPLA production.
Isolating the low yield of MeHPLA from the enantioselective reduction mixture 
was also labor intensive. The catalyst, MeHPLA, residual starting material, and major 
product were separated from the reaction mixture exclusively by HPLC on a semi- 
preparatory Cl 8 Ag-column. This method yielded pure samples of MeHPLA, however, 
many hours were sacrificed collecting product as it eluted from the semi-prep column.
The final recovery o f MeHPLA from the catalytic reduction was approximately 2%.
The diastereomeric method for the synthesis of the enantiomers o f MeHPLA was 
superior to the enantioselective reduction for several reasons. First, the yield of the 
enantiomers was approximately 23-fold greater. The final yield for the diastereomeric
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separation was approximately 46%. The reaction needed no intense monitoring because 
there were no side reactions that could destroy the desired product. Shortly after the 
chiral amine and racemic HPLA dissolved in THF, crystals o f the L-salt began to 
precipitate. Purification of the racemates o f HPLA was done by harvesting the crystals, 
acidifying in an aqueous solution, and extracting o f the HPLA with ethyl acetate. This 
yielded samples that were approximately 95% L-HPLA and 85% D-HPLA. The amount 
of enantiomeric purity was quantified by direct injection on the OA 5000 column.
The quantification of enantiomeric purity from the enantioselective reduction 
required the development of additional chemical procedures. Originally, quantification 
was attempted by hydrolyzing the methyl group of MeHPLA and then injecting the 
subsequent HPLA on the OA 5000 column. However, the hydrolysis o f MeHPLA lead to 
the production of an enolate anion because o f the acidity o f the proton at the chiral center. 
The acid-base chemistry at the chiral center was faster than the hydrolytic chemistry of 
the ester group. The strong base quickly reacted with the acidic proton on the chiral 
carbon, destroying the chiral center. Upon neutralization o f the reaction, the chiral center 
was reprotonated to yield equal amounts o f  the L and D-enantiomer. This was confirmed 
by injection of the hydrolysis product on to the OA 5000 column to find that the 
enantiomers were present in equal quantities.
Another method was discovered that could be used to quantify the 
enantioselectivity of the catalyst. Diastereomers of MeHPLA could be made by 
derivatizing the hydroxyl groups o f MeHPLA with enantiomerically pure methyl 
chloroformate (44). This would create diastereomers o f L and D-MeHPLA which could
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then be quantified by HPLC or GC-MS. Although this method was very promising, it 
was still labor intensive in comparison the diasteremeric separation o f HPLA with the 
chiral amine. Using the diastereomeric separation of HPLA, the product could be 
injected directly on the OA 5000 column after the recrystalization step or after the 
organic extraction step to quantitate the amount o f each enantiomer present 
Type IIEBS Binding Study
Binding studies with the L/D enantiomers of MeHPLA suggested that there may 
be stereospecificity associated with the ligand binding domain (LBD) o f the type Q EBS. 
Our study showed that L-MeHPLA had a 26% greater affinity for the type n  EBS than D- 
MeHPLA. Asymmetry in the type II EBS LBD is consistent with what is known about 
the LBD of the type IE R  and other members of the steroid receptor superfamily. 
Mutational analysis of the type I ER has mapped specific amino acids that are necessary 
for the binding of estradiol to the receptor. Presently a group at Baylor University, lead 
by B. Markaverich, is working on the isolation and purification of the type II EBS. This 
will allow for the mapping of the receptor and the eventual mutational analysis o f the 
type II EBS LBD.
Because of the possible asymmetry of the type II EBS LBD, it is likely that the 
identity of the endogenous isomer of MeHPLA is the L-enantiomer. This projection idea 
is supported by several observations. First, only the L-isomer o f HPLA is found in the 
urine of patients with tyrosyluria. Second, the endogenous pathway for the enzymatic 
synthesis of HPLA would only produce the L-isomer, because naturally occurring 
enzymes such as LDH and malate dehydrogenase are specific for the production of L-
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enantiomers. If the L-HPLA is the endogenous starting material for the synthesis o f 
MeHPLA, one would expect MeHPLA to be the L-isomer. Also, specific esterase activity 
is believed to cleave the methyl group from MeHPLA to produce HPLA. If HPLA from 
the enzymatic cleavage of MeHPLA were the D-isomer, it could be detected as such. 
However, all detectable HPLA has been the L-enantiomer. D-MeHPLA or D-HPLA 
have not been detected as a consequence of any anabolic or catabolic pathway.
Cell Growth Studies on MCF-7 and MDA-231 Breast Cancer Cells
Enantioselective binding of MeHPLA to the type II EBS did not translate into 
superior inhibitory activity for either MCF-7 or MDA-231 cells. Both L and D-MeHPLA 
suppressed the growth of breast cancer cells in vitro, however, no significant difference 
was found in their ability to suppress cellular proliferation in the 2 - 10 pg/ml range. A 
possible reason for this finding may be due to concentration effects that have been 
observed with other chiral molecules under physiological conditions.
For example, L and D-thalidamide show a concentration dependent suppression of 
the release of Tumor Necrosis Factor-alpha (TNF-alpha). At low concentrations (5-12.5 
|ig/ml), both enantiomers inhibit the release o f  TNF-alpha equally (45). However, at high 
concentrations (25-50 pg/ml), there was a weak but statistically significant selectivity 
toward L-thalidomide (45).
In a related experiment, the opposite concentration effect was observed in the 
ability of the enantiomers of leucine to replace each other in an acid-extractable pool of 
mammalian cells. At high concentrations (millimolar range), L and D-leucine had similar 
cellular uptake and displacement properties (46). However, below the millimolar
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concentration range, there was a distinct difference in the ability of L and D-leucine to be 
incorporated into the acid-extractable cell pool (46). Unlabeled L-leucine displaced an 
equivalent amount of labeled D-leucine from a preloaded acid-extractable pool (46). 
Similar differences were observed with other amino acids, including histidine, isoleucine, 
and phenylalanine (46).
Both of the preceding examples show that concentration dependent differences 
found in the utilization of chiral molecules can be found under physiological conditions. 
For this study, equivalent concentrations of L and D-MeHPLA had the same effect on 
cellular proliferation, despite their unequivalent ability of bind the type II EBS. Data 
from tritiated-MeHPLA studies showed that 1% of MeHPLA is incorporated into cells 
dosed with a concentration range of 1 to 10 mg/ml (3). Therefore, the intracellular 
concentration of MeHPLA incorporated into MCF-7 and MDA-231 cells was actually 1 
to 10 ng/ml or 102 to 510 nM. This concentration range corresponds well with the 
binding studies which had a concentration range of 10 to 100000 nM. Thus, it appears 
that for equivalent concentrations of the enantiomers of MeHPLA, binding affinity is not 
related to cell growth inhibition. As observed with the enantiomers of thalidamide, low 
concentrations have an equivalent effect on TNF-alpha release, while high 
concentrations, show significant enantiomeric specificity. Though, MCF-7 and MDA- 
231 cells were treated with microgram analyte quantities, the intracellular concentration 
was significantly lower, in the nanogram range.
It is therefore conceivable that this concentration dependent effect observed with 
the enantiomers of thalidamide may also be in operation with the enantiomers of
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MeHPLA. The next step in this study would be to increase the concentration of 
MeHPLA. It is possible that at higher concentrations of MeHPLA a significant 
difference may be found in the ability o f the enantiomers to suppress cell growth.
Discrepancies in our findings may possibly be related to mutations within the type 
II EBS itself. Cell growth studies performed by B. Markaverich showed significantly 
better cellular suppression for the same concentration range as used in our study. It is 
conceivable that genetic changes have occurred in the type II EBS, since the cells have 
gone through a number o f passages. This observation and the concentration differences 
discussed previously could possibly explain the discrepancies in cellular growth 
suppression seen for the two studies.
Molecular Opposition to Estrogen
Unopposed estrogen, described as “estrogen dominance”, is the main cause of 
most uterine cancers and at least one third o f all breast cancers (47). Molecular 
opposition to estrogen stimulated cellular proliferation is a recurring treatment in the 
battle against estrogen dependent cancers. The best example o f this style o f therapy is the 
drug tamoxifen which binds effectively with the type I ER and interrupts its ability to 
activate transcription. Interestingly, nature has provided mechanisms that have the same 
ability to oppose estrogen stimulation.
Natural compounds like MeHPLA and compounds known as “phytoestrogens,” 
also appear to work in opposition to estrogen and provide a protective value against 
hormone dependent cancers. In this study, MeHPLA has been demonstrated once again 
to suppress the growth of breast cancer cells in vitro. Because of its strong interaction
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with the type II EBS, the current thinking is that MeHPLA is a mediator of cellular 
suppression by its interaction with this receptor. A plausible mechanism o f interaction 
involves MeHPLA binding the type H EBS. This complex then interacts with an 
enhancer region o f the DNA to suppress transcription. This mechanism is supported by 
the observation that when estrogen is present the binding affinity o f MeHPLA for the 
type II EBS is decreased at low concentrations of MeHPLA and cell inhibition is 
reversed. In this scenario, an increase in type II EBS’s is observed in the cellular matrix 
upon estrogen stimulation. Estrogen’s ability to change the binding affinity o f the type II 
EBS for MeHPLA may account for this sudden increase in type II EBS concentration (2). 
However, at increased concentrations o f MeHPLA, inhibition is restored (2).
Our study showed that for the enantiomers o f MeHPLA, in the absence o f 
estrogen, there was no significant difference in their ability to suppress cellular 
proliferation, even though there was a significant difference in the enantiomers’ ability to 
bind the type II EBS. This indicates that a more complicated mechanism may exist for 
the interaction o f MeHPLA in which multiple mechanisms of suppression may be 
responsible for effecting cell growth. This type of mechanism is not uncommon and has 
been noted in the interaction o f dietary phytoestrogens with normal and malignant cells.
For example, dietary phytoestrogens have been demonstrated as effective binders 
to the type II EBS. Though designated the “bioflavanoid receptor”, the mechanism of 
phytoestrgoen-type II EBS cellular suppression is unclear and in some cases, data 
suggests that interaction with the type II EBS is not the main effector of cellular 
suppression (48). In fact, it appears that phytoestrogens compete with endogenous
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estrogens for the active site of estrogen biosynthesizing and metabolizing enzymes and 
thus reduce the concentration of biologically active endogenous estrogen (48).
Phytoestrogens, like genistein, have been demonstrated to inhibit protein tyrosine 
kinases (49). Oncogenes produce mutated cellular proteins that catalyze the 
autophosphorylation of tyrosine kinases. The phytoestrogen, genistein, is able to block 
this auto-catalysis. Also, in vitro experiments, genistein inhibited the phosphorylation of 
natural and artificial substrates of protein tyrosine kinases (49).
Other phytoestrogens interfere with the biosynthesis of estrogen. Compounds 
such as coumestrol, coumarin, and quercetin inhibit the reduction of estrone to active 
estradiol by the estrogen specific enzyme, 17p-hydroxysteroid oxidoreductase type I 
(17P-HSD type I) (48). These compounds are found in leguminous plants, beans, fruits, 
and vegetables. 17P-HSD type I is expressed in steroidgenic cells and placental cells, as 
well as in normal and malignant breast and endometrial tissue.
Phytoestrogens have been demonstrated to be inhibitors of DNA topoisomerases 
(49). The structure of genistein and other phytoestrogens allows them to intercalate 
between DNA strands. Geinistein inhibits the DNArDNA topoisomerase complex by 
stabilizing the complex causing strand breaks during replication. This fragmentation of 
DNA may result in the programmed cell death (apoptosis) o f rapidly growing malignant 
tissue.
Phytoestrogens may also help to prevent cancer as a result of their biological 
antioxidant properties (50). Reactive oxygen species may interact with electron rich 
DNA and play an important role in mutagenesis and carcinogenesis. Phytoestrogens have
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been shown to inhibit the production o f peroxide in response to phorboi ester TPA in HL- 
60 cells and human polymorphonuclear cells (49). Evidence indicates that the inhibition 
is not simply caused by a chemical reaction between phytoestrogens and hydrogen 
peroxide, but at a biochemical level.
Since all o f the ramifications concerning the specific biological mechanisms for 
the interaction o f MeHPLA is not known, to suggest that its ability to suppress cellular 
proliferation may only be due to its interaction with the type II EBS is premature. Since, 
there is a strong possibility that MeHPLA is a metabolite o f bioflavonoid/phytoestrogen 
degradation, it may retain many o f the properties o f its’ precursors and have several 
mechanisms for the suppression o f cell growth. It is also possible that all bioflavonoids 
degrade to MeHPLA and that it is MeHPLA that is doing all these things. This would 
correlate to the observations seen with the enantiomers of MeHPLA.
A Link Between MeHPLA, Phytoestrogens, Xenoestrogens and Cancer
The endogenous compound MeHPLA and phytoestrogens have been observed to 
be disrupters of endocrine and reproductive function. Extreme cases of phytoestrogen 
interaction have been documented in quail, deer mice, and livestock (51). In these cases, 
phytoestrogen accumulation has lead to infertility in the adults o f these species.
However, phytoestrogen accumulation is rare because most o f these compounds are 
metabolized and excreted from the host (51). For example, if MeHPLA is a metabolite of 
phytoestrogens, it is further metabolized by specific esterases and the resulting HPLA is 
excreted in urine. It has been hypothesized that the ability of certain plants to render 
predators infertile is an evolutionary response of the plant to protect its’ species (51).
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However, in most cases, evolution has a double edged sword, in which, predators are also 
able to adapt to the toxin and therefore extinguish its’ effects. Such is the case for insects 
and bacteria, which have many generations in a short period. In this case, insects are able 
to adapt to poisons quickly and bacteria can quickly adapt to antibiotic therapies.
But, in the adaptation o f animals to phytoestrogen, the result has been more than 
just a means o f metabolizing toxic agents. Phytoestrogens have retained enough o f their 
endocrine disruptive properties so that they are therapeutic for the prevention o f hormone 
dependent malignancies, instead o f being harmful agents. However, an interesting 
correlation has been noted in recent years between phytoestrogens and a group of 
compounds now known as xenoestrogens.
Xenoestrogens are foreign compounds that act as endocrine disrupters (51).
These compounds number in the hundreds and include plastics, pesticides, and organics, 
such as PCB’s, DDT, and Furan. The toxicity o f these compounds have been most 
notably documented in the alligator population of Lake Apopka, FL (52-53). Alligator 
death and infertility has been linked to the accumulation o f toxic chemicals in the animals 
reproductive system, leading to follicle damage in the female and sertoli cell damage in 
the male (52-53). Lipid soluble xenoestrogens from chemical contamination had become 
part o f the ecosystem of Lake Apopka. Ultra-high concentration of xenoestrogens were 
found in plants and the fatty tissue o f animals which used that lake as a resource.
However, no xenoestrogens were found in the lake. All o f the contaminates had been 
moved from the waters to the tissues of species inhabiting the area.
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Like phytoestrogens, xenestrogens disrupt the endocrine and reproductive powers 
of the host. However, unlike phytoestrogens, xenoestrogens are nonbiodegradable and 
bioaccumulate in plants and animals. Subsequently, they are pasted from host to host 
along the food chain (51). The effects o f these xenoestrogens have shown up in salmon, 
trout, turtles, gulls, porpoises, and the Bald eagle (51). Sexual abnormalities and 
embryonic deformities were noted for all the previously mentioned animals. The 
evolutionary ability o f these animals to adapt to these toxins was diminished, because the 
number o f pollutants were excessive and higher animals do not have the ability to 
produce several generations in short periods as their insect and bacterial counterparts 
(51). Therefore, it appears that both phytoestrogens and xenoestrogens have caused 
reproductive anomalies in animals. However, the preponderance o f toxic chemicals and 
their tendency to bioaccumlate in the fatty tissue of animals make them particularly toxic.
Recently, it has been suggested that the kind o f follicular damage seen in female 
alligators may be a contributing factor to breast and uterine cancer in women (47). 
Unopposed estrogen is the major cause o f most uterine cancers and at least one-third of 
all breast cancers. It has been suggested that xenoestrogen damaged follicles in humans 
have led to a condition in which the natural hormones o f menstruating women have been 
adversely effected, so that estrogen is produced in preponderance without any natural 
opposition (47). It has been suggested that the natural opposer to estrogen is the 
hormone, progesterone (47).
Progesterone is one of the two main hormones made by the ovaries of women. 
Studies have shown that progesterone decreases the growth of human breast epithelial
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cells in vivo in the presence or absence of estradiol (54). While unopposed estrogen 
leads to the proliferation o f human breast epithelial cells (54). During the menstrual 
cycle, the release o f estrogen is followed by the subsequent secretion of progesterone 
from the corpus luteum after ovulation. If  follicles are damaged, as is the case with 
animals that have bioaccumlations of xenoestrogens, the corpus luteum is abnormal, and 
progesterone may not be produced or released. In a recent study, is was discovered that 
seven out o f eighteen women age 24 to 42 did not ovulate (55). Without ovulation, no 
egg is released, the corpus luteum is not formed, and no progesterone is produced. This 
absence of progesterone in woman creates this condition in which estrogen is unopposed. 
Therefore, the lack of progesterone has been linked to uterine and breast cancer, luteal 
phase failure and miscarriage, PMS, osteoporosis, and autoimmune disorders such as 
Lupus erythematosis and Hashimoto’s thyroiditis (47).
A classic example o f follicular damage was seen with the use of the xenoestrogen, 
diethylstilbesterol (DES). One o f the most susceptible times for xenoestrogen virulence 
is in the developing embryo. In the 1950’s, DES was given to women who had 
difficulties maintaining pregnancies. It was subsequently discovered that the female 
children of patients who received DES during their pregnancies had a greater chance of 
developing cancer of the uterus and cervix. In male children, DES therapy lead to 
undescended testes, lower sperm counts, penis abnormalities, and increase incidence of 
prostate cancer. In these cases, the xenoestrogen damage effected the reproductive 
systems of the offspring of the patients that received DES therapy.
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The same was true for the offspring of Florida alligators. Studies have looked at 
younger alligators and it was discovered that follicular and sertoli cell damage was 
already present even in the juvenile alligators. At 6 months of age, female alligators o f 
Lake Apopka were found to have plasma levels o f 17p~estradiol twice as high as 
alligators in control lakes (52). Juvenile male alligators were found to have low 
testosterone and undeveloped penises (53). Similar abnormalities were found in the 
Florida panther, in which male panthers had the same estradiol level as female panthers 
(56). Therefore, it appears that it is the offspring o f affected species that show the greatest 
abnormalities in their sexual development Wildlife studies demonstrate that both sexes 
are affected and experience modifications o f gonadal and reproductive tract development. 
The ultimate effect is the abnormal functioning, synthesis, and metabolism of 
reproductive hormones. Data from wildlife studies represent models for the possible 
interaction of xenoestrogen in humans and may help to explain the increasing number of 
malignant diseases.
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Summary
MeHPLA, phytoestrogens, xenoestrogens and cancer are linked. Phytoestrogens 
are plant compounds that have been demonstrated to have cancer protective properties 
through various biological mechanisms. Phytoestrogens and xenoestrogens have been 
documented as causing infertility in several animal species. However, phytoestrogens are 
biodegradable and do not bioaccumlate in the animals, therefore adaptive evolution has 
provided animals with the means o f metabolizing phytoestrogens, while harnessing their 
power for protection against disease. Unlike phytoestrogens, xenoestrogen are not 
biodegradable and bioaccumulate in the fatty tissue of animals. In the last few years, 
hundreds o f xenoestrogen have been discovered in animals that have fertility 
abnormalities and other reproductive tract anomalies. The preponderance of 
xenoestrogens have impaired the adaptive ability o f affected species to develop 
physiological mechanism to metabolize and excrete xenoestrogens.
A specific consequence o f xenoestrogen poisoning is the development o f the 
condition known as estrogen dominance. This excess of estrogen has been linked to 
breast and uterine cancer in humans. It appears that phytoestrogens play a role in 
providing protection against estrogen dominance in several ways. They inhibit specific 
enzymes that are involved in the biosynthesis o f estrogen. They inhibit DNA 
topoisomerases that are necessary for DNA replication and cellular proliferation. 
Phytoestrogens can intercalate between DNA stands in rapidly growing cancer cells 
causing strand breaks and the subsequent programmed death o f the cell. Phytoestrogens
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may also act as antioxidants by scavenging reactive oxygen species that may also 
contribute to genetic abnormalities.
Since there are several mechanisms of biological action for phytoestrogens, it is 
likely that MeHPLA may also have several points o f physiological interaction. Data 
from the study o f the enantiomers o f MeHPLA supports this conclusion. Both 
phytoestrogens and MeHPLA bind to the type H EBS. Phytoestrogen binding is not the 
major mechanism of cellular suppression. Since the L-MeHPLA has a greater affinity for 
the type II EBS than D-MeHPLA, it would be expected to have a greater biological 
activity. However, ER binding study data was obtained in cell free homogenates.
Growth studies were done on living cells. It is perhaps possible that cellular methylases 
neutralized exogenously supplied MeHPLA (57). This would reduce the concentration of 
L and D MeHPLA. If L-MeHPLA is the endogenous isomer, it is possible that 
methylases could metabolize it in preference to the D-isomer. Such a situation would 
possibly give the observed biological activity for the enantiomers. Since, this research 
has shown that L and D-MeHPLA have equivalent biological activity, it is also possible 
that the mechanism o f MeHPLA interaction is as varied as phytoestrogen interaction.
This evidence supports the theory that MeHPLA is a metabolite o f bioflavonoid 
/phytoestrogen degradation.
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Fig. 31. The Effects of L-MeHPLA on MCF-7 human breast cancer cell growth in vitro. Cell growth is determined by counting 































Fig. 32. The Effects of D-MeHPLA on MCF-7 human breast cancer cell growth in vitro. Cell growth is determined by counting
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Fig. 33. The Effects of Racemic MeHPLA on MCF-7 human breast cancer cell growth in vitro. Cell growth is determined by 
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Fig. 34. The Effects of L-MeHPLA on MDA-231 human breast cancer cell growth in vitro. Cell growth is determined by






























0 1 2 3 6
Days
♦  10 ug/ml 
—* — 8 ug/ml 
— 6 ug/ml 
—H— 4 ug/ml 
- O -  2 ug/ml
Fig. 35. The Effects of D-MeHPLA on MDA-231 human breast cancer cell growth in vitro. Cell growth is determined by 
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Fig. 36. The Effects of Racemic MeHPLA on MDA-231 human breast cancer cell growth in vitro. Cell growth is determined by





























Fig. 39. The Effects of D-MeHPLA on the growth of HxGC3 colon cancer cells in vitro. Cell growth is determined by counting
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Fig 40. The effects of L-MeHPLA on the growth of HxGC3 colon cancer cells in vitro. Cell growth is determined by counting the


































—• — 10 ug/ml 
— 8 ug/ml 
-t5— 5 ug/ml 
—H—4 ug/ml 
—O — 2 ug/ml
Fig, 41. The effects of racemic MeHPLA on the growth of HxGC3 colon cancer cells in vitro. Cell growth is determined by
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Fig. 42. The effects of D-MeHPLA on the growth of LNCap prostate cancer cells in vitro. Cell growth is determined by counting
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Fig 43. The effects of L-MeHPLA on the growth of LNCap prostate cancer cells in vitro. Cell growth is determined by counting
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Fig 44. The effects of racemic MeHPLA on the growth of LNCap prostate cancer cells In vitro. Cell growth is determined by
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